Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Karyopharm Reports First Quarter 2015 Financial Results and Highlights Recent Progress
May 11, 2015 7:00 AM EDTPositive Data in Difficult to Treat Cancers With Significant Unmet Need Further Supports Broad Clinical Development Campaign for Selinexor
Conference Call Scheduled for Today at 8:30 a.m. ET
NEWTON, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"Karyopharm and its collaborators presented a comprehensive body of data across its oncology pipeline, including a total of twenty-one... More
Karyopharm Reports First Quarter 2015 Financial Results and Highlights Recent Progress
May 11, 2015 7:00 AM EDTPositive Data in Difficult to Treat Cancers With Significant Unmet Need Further Supports Broad Clinical Development Campaign for Selinexor
Conference Call Scheduled for Today at 8:30 a.m. ET
NEWTON, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"Karyopharm and its collaborators presented a comprehensive body of data across its oncology pipeline, including a total of twenty-one... More
